The lancet oncology
-
The lancet oncology · Jan 2025
Comparative StudyColorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data.
Previous studies have shown that colorectal cancer incidence is increasing among younger adults (aged <50 years) in multiple high-income western countries in contrast with stabilising or decreasing trends in incidence in older adults (aged ≥50 years). This study aimed to investigate contemporary colorectal cancer incidence trends in younger adults versus older adults. ⋯ Intramural Research Program of the American Cancer Society, Cancer Grand Challenges, and National Institutes of Health.
-
The lancet oncology · Jan 2025
ReviewThe changing global landscape of national cancer control plans.
Global efforts to highlight cancer and non-communicable diseases (NCDs) as a growing burden were first raised in 2005 World Health Assembly Resolution 58.22 and reinforced with Resolution 70.12 and the Global NCD action plan in 2017. One common thread for addressing cancer burden was the need to articulate cancer priorities within a comprehensive national cancer control plan (NCCP). ⋯ The global review included 16 new questions related to cancer equity, pandemic preparedness, global WHO initiatives, evidence-based recommendations, and other emerging trends. The findings can guide country-level decision makers on improvements to deliver person-centred cancer services to reduce the cancer burden.
-
The lancet oncology · Jan 2025
ReviewPulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies.
Lung neuroendocrine neoplasms are a group of diverse, heterogeneous tumours that range from well-differentiated, low-grade neuroendocrine tumours-such as typical and atypical carcinoids-to high-grade, poorly differentiated aggressive malignancies, such as large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung cancer (SCLC). While the incidence of SCLC has decreased, the worldwide incidence of other pulmonary neuroendocrine neoplasms has been increasing over the past decades. In addition to the standard histopathological classification of lung neuroendocrine neoplasms, the introduction of molecular and sequencing techniques has led to new advances in understanding the biology of these diseases and might influence future classifications and staging that can subsequently improve management guidelines in the adjuvant or metastatic settings. ⋯ This Review explores the epidemiology, diagnosis, and staging of lung neuroendocrine neoplasms to date. In addition, we focus on the evolving molecular landscape and biomarkers, ranging from tumour phenotypes to functional imaging studies and novel molecular biomarkers. We outline the various clinical outcomes, challenges, the treatment landscape, ongoing clinical trials, and future directions.